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Materials Design Analysis Reporting (MDAR)  
Checklist for Authors 
 
The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences 
(see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt 
the MDAR framework for transparent reporting in manuscripts and other outputs.   Please refer to the MDAR Elaboration 
Document for additional context for the MDAR framework.   
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Materials 
 
Antibodies Yes  (indicate where provided: page no/section/legend) n/a 
For commercial reagents, provide supplier 
name, catalogue number and RRID, if available. 
Yes (Materials and Methods; Plasmids and antibodies)  
   
Cell materials Yes  (indicate where provided: page no/section/legend) n/a 
Cell lines: Provide species information, strain. 
Provide accession number in repository OR 
supplier name, catalog number, clone number, 
OR RRID 
Yes (Materials and Methods; Generation of stable HEK 
293 cell lines) 
 
Primary cultures: Provide species, strain, sex of 
origin, genetic modification status. 
 n/a 
   
Experimental animals Yes  (indicate where provided: page no/section/legend) n/a 
Laboratory animals: Provide species, strain, sex, age, 
genetic modification status. Provide accession 
number in repository OR supplier name, catalog 
number, clone number, OR RRID 
 
 n/a 
Animal observed in or captured from the 
field: Provide species, sex and age where 
possible 
 n/a 
Model organisms: Provide Accession number 
in repository (where relevant) OR RRID 
 n/a 
   
Plants and microbes Yes  (indicate where provided: page no/section/legend) n/a 
Plants: provide species and strain, unique accession 
number if available, and source (including location 
for collected wild specimens) 
 
 n/a 
Microbes: provide species and strain, unique 
accession number if available, and source 
Yes (Materials and Methods)  
   
Human research participants Yes  (indicate where provided: page no/section/legend) n/a 
Identify authority granting ethics approval (IRB or 
equivalent committee(s), provide reference number 
for approval.  
 
 n/a 
Provide statement confirming informed consent 
obtained from study participants. 
 
 n/a 
Report on age and sex for all study participants.  n/a 
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Design 
 
Study protocol Yes  (indicate where provided: page no/section/legend) n/a 
For clinical trials, provide the trial registration 
number OR cite DOI in manuscript. 
 
  
 n/a 
   
Laboratory protocol Yes  (indicate where provided: page no/section/legend) n/a 
Provide DOI or other citation details if detailed 
step-by-step protocols are available.  
 
 
 n/a 
   
Experimental study design (statistics details) Yes  (indicate where provided: page no/section/legend) n/a 
State whether and how the following have been 
done, or if they were not carried out. 
  
Sample size determination 
 
 n/a 
Randomisation 
 
 n/a 
Blinding 
 
 n/a 
Inclusion/exclusion criteria 
 
 n/a 
  
Sample definition and in-laboratory replication Yes  (indicate where provided: page no/section/legend) n/a 
State number of times the experiment was 
replicated in laboratory 
Yes, (Materials and Methods: Flow cytometry analysis of 
reporter cell lines/ In vitro translation in the PURE System 
and photocrosslinking) 
 
 
 
Define whether data describe technical or 
biological replicates 
Biological replicates  
   
Ethics Yes  (indicate where provided: page no/section/legend) n/a 
Studies involving human participants: State details 
of authority granting ethics approval (IRB or 
equivalent committee(s), provide reference 
number for approval.  
 n/a 
Studies involving experimental animals: State 
details of authority granting ethics approval (IRB or 
equivalent committee(s), provide reference 
number for approval. 
 n/a 
Studies involving specimen and field samples: State 
if relevant permits obtained, provide details of 
authority approving study; if none were required, 
explain why. 
 n/a 
   
Dual Use Research of Concern (DURC) Yes  (indicate where provided: page no/section/legend) n/a 
If study is subject to dual use research of concern, 
state the authority granting approval and 
reference number for the regulatory approval 
 n/a 
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Analysis 
 
Attrition Yes  (indicate where provided: page no/section/legend) n/a 
State if sample or data point from the analysis is 
excluded, and whether the criteria for exclusion 
were determined and specified in advance. 
 n/a 
   
Statistics Yes  (indicate where provided: page no/section/legend) n/a 
Describe statistical tests used and justify choice of 
tests. 
 
 n/a 
   
Data Availability Yes  (indicate where provided: page no/section/legend) n/a 
State whether newly created datasets are 
available, including protocols for access or 
restriction on access. 
Yes (Accession numbers in ‘Data and materials 
availability’ in acknowledgement section) 
 
If data are publicly available, provide accession 
number in repository or DOI or URL. 
Yes (Accession numbers in ‘Data and materials 
availability’ in acknowledgement section) 
 
If publicly available data are reused, provide 
accession number in repository or DOI or URL, 
where possible. 
Yes (Accession numbers of used data in Figure 4C 
legend, fig. S12 legend) 
 
   
Code Availability Yes  (indicate where provided: page no/section/legend) n/a 
For all newly generated code and software 
essential for replicating the main findings of the 
study: 
  
S ate whether the code or software is available.  n/a 
If code is publicly available, provide accession 
number in repository, or DOI or URL. 
 n/a 
 
Reporting 
 
Adherence to community standards Yes  (indicate where provided: page no/section/legend) n/a 
MDAR framework recommends adoption of 
discipline-specific guidelines, established and 
endorsed through community initiatives. Journals 
have their own policy about requiring specific 
guidelines and recommendations to complement 
MDAR.  
  
State if relevant guidelines (eg., ICMJE, MIBBI, 
ARRIVE) have been followed, and whether a 
checklist (eg., CONSORT, PRISMA, ARRIVE) is 
provided with the manuscript.  
 n/a 
 
 
